Introduction: In Canada, those who are or who could become pregnant are recommended to consume a daily multivitamin containing 400 μg of folic acid to help prevent neural tube defects.
Objectives: To report the prevalence and determinants of folic acid-containing supplement use among females of childbearing age in Canada.
Methods: Data were combined from cycles 2015/16 and 2017/18 of the maternal experiences module of the cross-sectional Canadian Community Health Survey, which was completed by females aged 15-55 years. Representative weighted estimates (means/percentages, 95% CI) were generated for folic acid-containing supplement use among all pregnant, non-pregnant, and lactating respondents. For those who had given birth in the preceding 5 years, estimates were also generated for supplement use in the 3 months before and first 3 months of their most recent pregnancy, and pre-pregnancy awareness of the link between folic acid and some birth defects. We examined associations with sociodemographic factors using multivariable logistic regression.
Results: Overall, 16.5% (15.9-17.0%) of non-pregnant, 80.3% (77.1-83.5%) of pregnant, and 58.4% (54.8-61.9%) of lactating females aged 15-55 reported using a folic acid-containing supplement. Among those who had given birth in the preceding 5 years, 63.7% (62.2-65.1%) consumed a folic acid-containing supplement in the 3 months prior to pregnancy, while 89.9% (88.8-90.9%) did so during the first trimester. Lower prevalence of supplement use before or during pregnancy was reported among the 23.7% (22.4-25.1%) of respondents unaware of the relationship between folic acid and birth defects. Younger age, single marital status, lower educational attainment, income below the median, and smoking were associated with lower odds of awareness or supplement use.
Conclusion: While most females living in Canada reported using folic acid-containing supplements prior to and during pregnancy, use of these supplements among non-pregnant females of childbearing age is low, and sociodemographic inequalities exist.
Clinical Trial Registry Number: not applicable REGISTRY AND REGISTRY NUMBER FOR SYSTEMATIC REVIEWS OF META-ANALYSIS: not applicable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tjnut.2025.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Folic acid-containing supplement use among females aged 15-55 in the Canadian Community Health Survey 2015-2018.
J Nutr
March 2025
Nutrition Research Division, Bureau of Nutritional Sciences, Food and Nutrition Directorate, Health Products and Food Branch, Health Canada, Ottawa, Ontario, Canada.
Introduction: In Canada, those who are or who could become pregnant are recommended to consume a daily multivitamin containing 400 μg of folic acid to help prevent neural tube defects.
Objectives: To report the prevalence and determinants of folic acid-containing supplement use among females of childbearing age in Canada.
Methods: Data were combined from cycles 2015/16 and 2017/18 of the maternal experiences module of the cross-sectional Canadian Community Health Survey, which was completed by females aged 15-55 years.
Background: Periodontal disease is a host-mediated inflammation caused due to microbial challenge. Hence, mechanisms involving the control of host-associated mediators can be a potential target. The conventional nonsurgical periodontal treatment modality includes scaling and root planing (SRP), which is often combined with adjunctive chemical plaque control agents for effective disease control.
View Article and Find Full Text PDFTumor-activated targetable photothermal chemotherapy using IR780/zoledronic acid-containing hybrid polymeric nanoassemblies with folate modification to treat aggressive breast cancer.
Nanoscale
January 2024
Department of Chemical Engineering, National Chung Hsing University, Taichung 402, Taiwan.
To effectively treat aggressive breast cancer by tumor-activated targetable photothermal chemotherapy, in this work, folate (FA)-modified hybrid polymeric nanoassemblies (HPNs) with a poly(ethylene glycol) (PEG)-detachable capability are developed as vehicles for tumor-targeted co-delivery of IR780, a lipophilic photothermal reagent, and zoledronic acid (ZA), a hydrophilic chemotherapy drug. Through hydrophobic interaction-induced co-assembly, IR780 molecules and ZA/poly(ethylenimine) (PEI) complexes were co-encapsulated into a poly(lactic--glycolic acid) (PLGA)-rich core stabilized by the amphiphilic FA-modified D-α-tocopheryl poly(ethylene glycol) succinate (FA-TPGS) and acidity-sensitive PEG-benzoic imine-octadecane (C18) (PEG--C18) conjugates. The developed FA-ZA/IR780@HPNs with high ZA and IR780 payloads not only showed excellent colloidal stability in a serum-containing milieu, but also promoted IR780-based photostability and photothermal conversion efficiency.
View Article and Find Full Text PDFLow-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial.
Am J Clin Nutr
March 2024
Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address:
Background: Folic acid supplementation during the periconceptional period reduces the risk of neural tube defects in infants, but concern over chronic folic acid exposure remains. An improved understanding of folate absorption may clarify potential risks. Folate transporters have been characterized in the small intestine, but less so in the colon of healthy, free-living humans.
View Article and Find Full Text PDFIntake and biomarkers of folate and folic acid as determinants of chemotherapy-induced toxicities in patients with colorectal cancer: a cohort study.
Am J Clin Nutr
February 2024
Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, the Netherlands.
Background: Capecitabine is an oral chemotherapeutic drug showing antitumor activity through inhibition of thymidylate synthase, an enzyme involved in folate metabolism. There are concerns about the high intake of certain vitamins, and specifically folate, during chemotherapy with capecitabine. Whether folate or folic acid, the synthetic variant of the vitamin, impact treatment toxicity remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!